King's College Hospital registers PK study of Gilead-partnered TAF regimen in kidney disease
A new observational trial will measure tenofovir alafenamide and emtricitabine blood levels in HIV patients with advanced kidney disease, sponsored by King's College Hospital NHS Trust with Gilead as collaborator.
This week's only update involves a single newly registered pharmacokinetic study tied to Gilead's antiretroviral portfolio.
- A new observational trial, "Tenofovir Exposures in People With HIV Who Have Advanced Chronic Kidney Disease and Are Receiving Tenofovir Alafenamide-containing Antiretroviral Therapy" (TEAK, NCT07812571), is not yet recruiting, sponsored by King's College Hospital NHS Trust with Gilead Sciences as a collaborator.1 The study plans to enroll 50 participants1 and will draw repeated blood samples over 24 hours from patients on standard tenofovir alafenamide/emtricitabine doses to measure drug and active metabolite levels in those with chronic kidney disease stages 4 and 3b.1 Estimated start is 2026-11-01, with primary completion expected 2027-06-30.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.